-
-
-
-
-
-
-
Cara Therapeutics (CARA) PT Lowered to $28 at Stifel
-
-
-
-
-
-
-
Cara Therapeutics (CARA) KARE Phase 2 Dose-Ranging Trial of Oral KORSUVA in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus Did Not Meet Primary Endpoint
-
-
-
-
-
-
-
Vifor Pharma and Cara Therapeutics (CARA) announce U.S. FDA acceptance and Priority Review of NDA for KORSUVA injection in hemodialysis patients with moderate-to-severe pruritus
-
-
-
-
-
14,982 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

